Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Combination of ZG006 for Injection with Etoposide and Cisplatin

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Combination of ZG006 for Injection with Etoposide and Cisplatin

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis